海創藥業(688302.SH):氘恩扎魯胺軟膠囊新藥上市申請獲得批准
格隆匯5月29日丨海創藥業(688302.SH)公佈,從國家藥品監督管理局網站查詢獲悉,公司自主研發的1類新藥海納安(通用名:氘恩扎魯胺軟膠囊)獲得國家藥監局批准上市,用於治療接受醋酸阿比特龍及化療後出現疾病進展,且既往未接受新型雄激素受體抑制劑的轉移性去勢抵抗性前列腺癌(mCRPC)成人患者。根據公開資料查詢,氘恩扎魯胺軟膠囊是國內第一款針對該類患者人羣獲得批准上市的創新藥物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.